Pancreatic cancer is an extremely lethal malignancy. On average, patients who are diagnosed with pancreatic cancer succumb to the disease within 6 months. Research is the only way to defeat pancreatic cancer. My lab is making progress toward finding a cure by detecting the disease earlier and designing novel therapeutic approaches.
David Tuveson’s laboratory uses murine and human models of pancreatic cancer to explore the fundamental biology of malignancy and thereby identify new diagnostic and treatment strategies. The lab’s approaches run the gamut from designing new model systems of disease to developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings. The lab’s studies make use of organoid cultures—three-dimensional cultures of normal or cancerous epithelia—as ex vivo models to probe cancer biology. Current projects in the lab explore changes in redox metabolism associated with pancreatic cancer tumorigenesis, dissect signaling by the Ras oncogene, discover new biomarkers of early pancreas cancer, and identify mechanisms of cross-talk between pancreatic cancer cells and the tumor stroma. Novel treatment approaches suggested by these studies are then tested by performing therapeutic experiments in mouse models. To dissect molecular changes associated with pancreatic tumorigenesis, the Tuveson lab has generated a large collection of human patient-derived organoid models. By measuring the therapeutic sensitivities of patient-derived organoids, the lab is working to identify novel strategies to treat patients as well as markers of therapeutic response. The Tuveson Laboratory maintains strong links to clinical research, and the ultimate goal is confirmation of preclinical findings in early-phase trials. Collectively, the lab’s bench-to-bedside approach is codified as the “Cancer Therapeutics Initiative,” and this initiative will provide these same approaches to the entire CSHL cancer community.
Dr. Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and the Chief Scientist for the Lustgarten Foundation.
CSHL receives 2021 NCI grant of $4.5 million
October 1, 2021
The National Cancer Institute renewed its Basic Laboratory Cancer Center grant for CSHL, marking 34 years of our continued progress in cancer research.
Mestag, co-founded by CSHL prof, named leading new biotech
September 27, 2021
Fierce Biotech named Mestag Therapeutics, co-founded by CSHL Professor David Tuveson, a 2021 “Fierce 15” leader in the biotech and pharma business.
CSHL organoid facility: Cancer custodians
July 2, 2021
To beat our worst enemy, we must first let it grow.
How pancreatic cancer cells dodge drug treatments
June 22, 2021
CSHL scientists discovered a new clue that might explain how some pancreatic cancers evade cancer-killing drugs.
June 8, 2021
Innovative research and educational activities never stopped during the COVID-19 pandemic.
$11 million investment to develop fibroblast therapeutic
April 26, 2021
CSHL Professor David Tuveson and other leading disease experts founded a company to target fibroblasts as a new way to treat cancer and inflammatory diseases.
Dr. David Tuveson inaugurated as AACR president
April 21, 2021
CSHL Cancer Center Director David Tuveson is leading the American Association for Cancer Research.
CSHL’s new organoid facility
November 5, 2020
The 2,200 square foot facility will make and maintain hundreds of live tissue models grown from patient tumors.
One experiment: Organoids as living laboratories
October 30, 2020
These tiny balls of cells are revolutionizing the research and treatment of pancreas and other types of cancers.
New genetic research to understand racial disparity in cancers
September 8, 2020
Cold Spring Harbor Laboratory will study the genetic contributions of ethnicity to colon, endometrial, and pancreas cancers in African Americans.